Literature DB >> 11704640

Commercial taxane formulations induce stomatocytosis and increase blood viscosity.

M Mark1, R Walter, D O Meredith, W H Reinhart.   

Abstract

1. Taxanes are antineoplastic drugs which have cardiovascular side effects of unknown mechanism. We investigated their influence on blood viscosity and erythrocyte morphology. 2. Whole blood was incubated in vitro with increasing concentrations of Taxol, Taxotere, paclitaxel (0-100 microM) and the vehicles Cremophor-EL and Tween 80 (0-5% vol) for 1 h at 37 degrees C. Plasma and whole blood viscosity (Haematocrit 45%) were measured and erythrocyte morphology was assessed on glutaraldehyde-fixed cells. The same investigations were performed in seven patients before and after a Taxol-infusion. 3. Taxol and Taxotere induced a dose- and time-dependent stomatocytic shape transformation of erythrocytes. Paclitaxel alone had no effect, but the vehicles cremophor-EL and Tween 80, used in Taxol and Taxotere, respectively, induced a comparable degree of stomatocytosis. This suggests a preferential intercalation of these substances into the inner hemileaflet of the membrane lipid bilayer. Associated with this shape change a dose-dependent increase in plasma and whole blood viscosity was observed. Neither shape nor viscosity changes were reversible upon removal of the agents. After the infusion of 130-300 mg Taxol in patients a slight shift towards stomatocytosis and an increase in whole blood viscosity at high shear rate from 5.09+/-0.30 to 5.44+/-0.38 mPa.s (P<0.05) were confirmed. 4. Commercial taxane drug formulations induce stomatocytosis and increase blood viscosity, which is due to their formulation vehicles. These findings may contribute to the understanding of the cardiovascular side effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704640      PMCID: PMC1573070          DOI: 10.1038/sj.bjp.0704387

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood.

Authors:  W H Reinhart; G M Baerlocher; T Cerny; G R Owen; H J Meiselman; J H Beer
Journal:  Eur J Haematol       Date:  1999-04       Impact factor: 2.997

2.  Red cell shapes. An illustrated classification and its rationale.

Authors:  M Bessis
Journal:  Nouv Rev Fr Hematol       Date:  1972 Nov-Dec

3.  Rheology of shape-transformed human red cells.

Authors:  H J Meiselman
Journal:  Biorheology       Date:  1978       Impact factor: 1.875

4.  The influence of erythrocyte shape on suspension viscosities.

Authors:  W H Reinhart; M Singh-Marchetti; P W Straub
Journal:  Eur J Clin Invest       Date:  1992-01       Impact factor: 4.686

Review 5.  The taxanes: an update.

Authors:  J Crown; M O'Leary
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

6.  Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.

Authors:  M Hidalgo; C Aylesworth; L A Hammond; C D Britten; G Weiss; J Stephenson; G Schwartz; A Patnaik; L Smith; K Molpus; S Felton; E Gupta; K J Ferrante; A Tortora; D S Sonnichsen; J Skillings; E K Rowinsky
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

7.  Equilibrium and kinetic effects of drugs on the shapes of human erythrocytes.

Authors:  M P Sheetz; S J Singer
Journal:  J Cell Biol       Date:  1976-07       Impact factor: 10.539

8.  Membrane microfilaments of erythrocytes: alteration in intact cells reproduces the hereditary spherocytosis syndrome (vinblastine-colchicine-strychnine-electron microscopy-cell rigidity).

Authors:  H Jacob; T Amsden; J White
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

9.  Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group.

Authors:  B J Roth; B Y Yeap; G Wilding; B Kasimis; D McLeod; P J Loehrer
Journal:  Cancer       Date:  1993-10-15       Impact factor: 6.860

Review 10.  A reassessment of cardiac toxicity associated with Taxol.

Authors:  S G Arbuck; H Strauss; E Rowinsky; M Christian; M Suffness; J Adams; M Oakes; W McGuire; E Reed; H Gibbs
Journal:  J Natl Cancer Inst Monogr       Date:  1993
View more
  6 in total

1.  Blood viscosity as a sensitive indicator for paclitaxel induced oxidative stress in human whole blood.

Authors:  Gamaleldin I Harisa
Journal:  Saudi Pharm J       Date:  2014-04-30       Impact factor: 4.330

2.  Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Authors:  Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

3.  New cutaneous toxicities with generic docetaxel: are the excipients guilty?

Authors:  Margarita Garrido-Siles; Jose Javier Arenas-Villafranca; Elísabeth Pérez-Ruiz; M Francisca de Linares Fernández; Begoña Tortajada; Francisco Rivas-Ruiz; Vicente Faus; Antonio Rueda
Journal:  Support Care Cancer       Date:  2014-12-10       Impact factor: 3.603

4.  Toxicities of docetaxel: original drug versus generics-a comparative study about 81 cases.

Authors:  Choukri Elm'hadi; Rachid Tanz; Mohamed Reda Khmamouche; Mehdi Toreis; Tarik Mahfoud; Khaoula Alaoui Slimani; Hassan Errihani; Mohammed Ichou
Journal:  Springerplus       Date:  2016-06-16

Review 5.  Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.

Authors:  Muhammad Farhan Sohail; Mubashar Rehman; Hafiz Shoaib Sarwar; Sara Naveed; Omer Salman; Nadeem Irfan Bukhari; Irshad Hussain; Thomas J Webster; Gul Shahnaz
Journal:  Int J Nanomedicine       Date:  2018-06-08

Review 6.  Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.

Authors:  Ruben A G van Eerden; Ron H J Mathijssen; Stijn L W Koolen
Journal:  Int J Nanomedicine       Date:  2020-10-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.